The stock of e-Therapeutics plc (LON:ETX) reached all time low today, Nov, 22 and still has GBX 7.64 target or 8.00% below today’s GBX 8.30 share price. This indicates more downside for the GBX 22.28 million company. This technical setup was reported by Barchart.com. If the GBX 7.64 PT is reached, the company will be worth GBX 1.78M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 0.90% or GBX 0.07 on November 22, hitting GBX 8.3. About 14,771 shares traded hands. e-Therapeutics plc (LON:ETX) has declined 42.24% since April 22, 2016 and is downtrending. It has underperformed by 46.80% the S&P500.
More notable recent e-Therapeutics plc (LON:ETX) news were published by: Businesswire.com which released: “e-Therapeutics plc Announces Full Year Results” on March 31, 2015, also Medgadget.com with their article: “e-Therapeutics Plc Clinical Trial Review, Market Growth, Trends and Clinical …” published on November 16, 2016, Fool.Co.Uk published: “Should You Buy Gulf Marine Services PLC, IQE plc And e-Therapeutics plc After …” on March 22, 2016. More interesting news about e-Therapeutics plc (LON:ETX) were released by: Businesswire.com and their article: “e-Therapeutics reports positive interim results from UK phase Ia trial of …” published on March 31, 2014 as well as Businesswire.com‘s news article titled: “e-Therapeutics Starts Phase IIb Trial of ETS6103 in Major Depressive Disorder” with publication date: October 31, 2013.
e-Therapeutics plc is a United Kingdom drug discovery and development company. The company has a market cap of 22.28 million GBP. The Company’s discovery platform is based on the network of pharmacology and chemical biology. It currently has negative earnings. The Firm operates in the business segment of drug discovery and development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.